Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Aisha Lateef

Showing results (21-30 of 54) with videos related to

Pageof 6
Sort By:
Singapore Medical Journal|August 2, 2023
Recommendations for enhanced primary series (third dose) COVID-19 vaccination for people with rheumatic diseases: Chapter of Rheumatologists, College of Physicians, SingaporeChuanhui Xu, Manjari Lahiri, Amelia Santosa, et al.
International Journal of Rheumatic Diseases|May 11, 2021
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of RheumatologistsAmelia Santosa, Chuanhui Xu, Thaschawee Arkachaisri, et al.
The Lancet. Rheumatology|January 23, 2024
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort studyDiane Apostolopoulos, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
The Lancet. Rheumatology|January 17, 2024
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
The Lancet. Rheumatology|January 17, 2024
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
Pharmacogenomics|June 9, 2017
Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approachWei Chuen Tan-Koi, Cynthia Sung, Yong Yeow Chong, et al.
Arthritis Research & Therapy|March 22, 2017
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective studyVera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi, et al.
Arthritis Research & Therapy|November 11, 2016
Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohortVera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi, et al.
Rheumatology (Oxford, England)|March 11, 2021
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational studyRangi Kandane-Rathnayake, Worawit Louthrenoo, Vera Golder, et al.
Lupus Science & Medicine|January 20, 2025
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosusRangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, et al.
Pageof 6

Showing results (21-30 of 54) with videos related to

Sort By:
Pageof 6
Singapore Medical Journal|August 2, 2023
Recommendations for enhanced primary series (third dose) COVID-19 vaccination for people with rheumatic diseases: Chapter of Rheumatologists, College of Physicians, SingaporeChuanhui Xu, Manjari Lahiri, Amelia Santosa, et al.
International Journal of Rheumatic Diseases|May 11, 2021
Recommendations for COVID-19 vaccination in people with rheumatic disease: Developed by the Singapore Chapter of RheumatologistsAmelia Santosa, Chuanhui Xu, Thaschawee Arkachaisri, et al.
The Lancet. Rheumatology|January 23, 2024
Factors associated with damage accrual in patients with systemic lupus erythematosus with no clinical or serological disease activity: a multicentre cohort studyDiane Apostolopoulos, Rangi Kandane-Rathnayake, Worawit Louthrenoo, et al.
The Lancet. Rheumatology|January 17, 2024
Evaluation of remission definitions for systemic lupus erythematosus: a prospective cohort studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
The Lancet. Rheumatology|January 17, 2024
Lupus low disease activity state as a treatment endpoint for systemic lupus erythematosus: a prospective validation studyVera Golder, Rangi Kandane-Rathnayake, Molla Huq, et al.
Pharmacogenomics|June 9, 2017
Tailoring of recommendations to reduce serious cutaneous adverse drug reactions: a pharmacogenomics approachWei Chuen Tan-Koi, Cynthia Sung, Yong Yeow Chong, et al.
Arthritis Research & Therapy|March 22, 2017
Association of the lupus low disease activity state (LLDAS) with health-related quality of life in a multinational prospective studyVera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi, et al.
Arthritis Research & Therapy|November 11, 2016
Frequency and predictors of the lupus low disease activity state in a multi-national and multi-ethnic cohortVera Golder, Rangi Kandane-Rathnayake, Alberta Yik-Bun Hoi, et al.
Rheumatology (Oxford, England)|March 11, 2021
Independent associations of lymphopenia and neutropenia in patients with systemic lupus erythematosus: a longitudinal, multinational studyRangi Kandane-Rathnayake, Worawit Louthrenoo, Vera Golder, et al.
Lupus Science & Medicine|January 20, 2025
Longitudinal associations of flare and damage accrual in patients with systemic lupus erythematosusRangi Kandane-Rathnayake, Dominique Milea, Worawit Louthrenoo, et al.
Pageof 6